TrialJournal for immunotherapy of cancer2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Mohammed M Milhem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.